PTK2 is a potential biomarker and therapeutic target for EGFR- or TLRs-induced lung cancer progression via the regulation of the cross-talk between EGFR- and TLRs-mediated signals

• Váldodahkkit: Ji Young Kim (Dahkki), Ji Hye Shin (Dahkki), Mi-Jeong Kim (Dahkki), Bongkum Choi (Dahkki), Yeeun Kang (Dahkki), Jimin Choi (Dahkki), Seo Hyun Kim (Dahkki), Dohee Kwan (Dahkki), Duk-Hwan Kim (Dahkki), Eunyoung Chun (Dahkki), Ki-Young Lee (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: BMC, 2024-05-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract Protein tyrosine kinase 2 (PTK2), epidermal growth factor receptor (EGFR), and toll-like receptor (TLRs) are amplified in non-small cell lung cancer (NSCLC). However, the functional and clinical associations between them have not been elucidated yet in NSCLC. By using microarray data of non...